Kiadis receives $3.9M boost for blood cancer trial

06/27/2013 | Genetic Engineering & Biotechnology News

A division of the Netherlands' Ministry of Economic Affairs granted Kiadis Pharma a loan worth around $3.9 million to support midstage trials of ATIR. The drug candidate is designed to permit stem cell transplantations for blood cancer patients with partially mismatched or haploidentical donors.

View Full Article in:

Genetic Engineering & Biotechnology News

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior Attorney
Blue Cross Blue Shield of Louisiana
Baton Rouge, LA
Senior or Principal Consultant
PAREXEL International
Nationwide, SL_Nationwide
Chief Financial Officer
Health Alliance Plan of Michigan
Southfield, MI
Senior Vice-President Managed Care Mid-Atlantic Region
Mercy Health System
Conshohocken, PA
Associate Chief Financial Officer
Commonwealth Care Alliance
Boston, MA